Skip to main content
. 2013 May 22;38(6):629–637. doi: 10.1093/jpepsy/jst032

Table I.

Blood Glucose Monitoring (BGM) and HbA1c Pre- and PostTreatment

Subject BGM times per day
HbA1c %
First week of treatment Last week of treatment Intake End of treatment 3 months after treatment
01 1.2 6.3 10.9 8.7 11.1
02 6.7 10.0 8.4 8.4 8.1
03 0.8 3.3 13.6 10.2 12.3
04 2.4 7.1 10.2 8.8 7.9
05 3.7a 11.9 10.4 9.2
06 4.4 6.7 8.5 9.0b 8.5
07 7.0 6.7 14.0c 10.6 10.3
08 3.6 4.4d 11.1 10.1
09 3.7 6.6 14.0c 8.8 11.3
10 3.7 5.9e 9.5 8.6 9.3
11 0.6a 14.0c 8.9 8.5
12 5.9 1.3e 14.0c 10.3
13 5.7 7.6 16.8b 9.1 9.9
14 4.6 6.1 9.9 7.9
15 4.5 7.6 8.6 8.0 8.2
16 4.1 7.7 12.2 7.7 11.6
17 4.0 6.9 9.9 9.4b 10.3b
M (SD) 4.1 (1.9) 6.3 (2.0) 11.6 (2.5) 9.1 (0.9) 9.8 (1.4)

aThese two participants did not complete treatment and did not provide meter data at the end of treatment assessment.

bValue obtained via laboratory blood test.

cValues of “>14.0” using point of care testing were scored as 14.0 for analyses.

dThis participant moved away unexpectedly in week 9 of treatment and did not have access to a computer. This participant’s week 9 data were used above as the end of treatment value.

eThese two participants did not complete treatment but did provide meter data at the end of treatment assessment.